Determining factors of the response to hyperhomocysteinemia treatment in renal transplant patients.
Hyperhomocysteinemia (hyperHcy) is a risk factor for cardiovascular disease. The benefits of lowering homocysteinemia (Hcy) in renal transplant recipients through vitamin treatment are not clearly understood. The objective of this study was to establish the demographic, renal, Hcy metabolism, and microinflammation factors that determined the response to folic acid and vitamin B complex treatment in stable patients with renal transplants and hyperHcy. We studied 65 renal transplant patients with baseline hyperHcy. The mean baseline Hcy level of these patients was 22.5 micromol/L. Following treatment it fell to 14.5 micromol/L, an overall reduction of 35.5%. Forty-one patients (63%) were classified as responders; the remainder (37%), nonresponders. A bivariance analysis suggested the only significant differences between responding and nonresponding patients were the pre-treatment Hcy level and the renal function level.
Díaz
J M
JM
Renal Transplant Unit, Nephrology Department, Fundació Puigvert, Universitat Autónoma Barcelona, Spain. jdiaz@fundacio-puigvert.es
Sainz
Z
Z
Gich
I
I
Guirado
L L
LL
Puig
T
T
Oliver
A
A
Montañés
R
R
Facundo
C
C
Chuy
E
E
Solà
R
R
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D005260:Female; D005492:Folic Acid / Q000097:blood / Q000627:therapeutic use*; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000188:drug therapy*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000097:blood / Q000188:drug therapy*; D012372:ROC Curve; D016896:Treatment Outcome; D014805:Vitamin B 12 / Q000627:therapeutic use*
D006710:Homocysteine; D005492:Folic Acid; D014805:Vitamin B 12